Publication | Closed Access
Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study
118
Citations
22
References
2002
Year
Pegylated IFNalpha-2b was active and well tolerated in patients with metastatic solid tumors, including RCC, at doses up to 6.0 micro g/kg/wk.
| Year | Citations | |
|---|---|---|
Page 1
Page 1